Stephane Girault

Limoges, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Limoges, FR 

Overview

Stephane Girault practices practicing medicine in Limoges, France.

Her clinical expertise encompasses Blood Clots, Purpura, Chronic Graft Versus Host Disease (cGvHD), Adult Immune Thrombocytopenia, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Limoges, France
Other Locations
Angers, France
Brive-la-gaillarde, France
Rennes, France
Vandoeuvre-les-nancy, 54500, France
Nantes, France
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Enrollment Status: Recruiting
Publish Date: March 20, 2026
Intervention Type: Drug
Study Drugs: Direct Oral Anticoagulants, Low-Dose Aspirin
Study Phase: Phase 3
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Other
A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
Enrollment Status: Completed
Publish Date: July 09, 2021
Intervention Type: Drug
Study Drug: Daratumumab
Study Phase: Phase 2
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®
Enrollment Status: Completed
Publish Date: October 16, 2019
Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.
Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.
Enrollment Status: Completed
Publish Date: July 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

29 Total Publications

Clinical value of artificial intelligence in reducing PET image acquisition time: routine clinical validation using qualitative, quantitative, and radiomic analysis on a cohort of 282 patients undergoing [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT.
Clinical value of artificial intelligence in reducing PET image acquisition time: routine clinical validation using qualitative, quantitative, and radiomic analysis on a cohort of 282 patients undergoing [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT.
Journal: EJNMMI physics
Published: August 29, 2025

Frequently Asked Questions about Stephane Girault

Is Stephane Girault a top-rated expert for Blood Clots?

MediFind is an objective health platform that identifies experts based on real-world data. Stephane Girault is classified as an Experienced expert for Blood Clots, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stephane Girault participate in research or clinical trials?

Yes. Stephane Girault has published 29 articles and abstracts on conditions like Blood Clots. You can view a list of Stephane Girault's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Girault's expertise for a condition
ConditionClose
        View All 15 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile